{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:16:56Z","timestamp":1785025016360,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-024-01568-8","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T20:02:14Z","timestamp":1727899334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Public perceptions related to healthcare preparedness to anti-amyloid therapies for Alzheimer\u2019s Disease in Japan"],"prefix":"10.1186","volume":"16","author":[{"given":"Kenichiro","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuaki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensaku","family":"Kasuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Awata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Iwatsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"issue":"10","key":"1568_CR1","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S1474-4422(22)00298-8","volume":"21","author":"CR Jack Jr","year":"2022","unstructured":"Jack CR Jr. Advances in Alzheimer\u2019s disease research over the past two decades. Lancet Neurol. 2022;21(10):866\u20139.","journal-title":"Lancet Neurol"},{"key":"1568_CR2","unstructured":"Kyushu Daigaku. Survey on about pevalence and future estimates of dementia and mild cognitive impairment. [Article in Japanese] (https:\/\/www.eph.med.kyushu-u.ac.jp\/jpsc\/uploads\/resmaterials\/0000000111.pdf?1715072186): Accessed on 25 July 2024."},{"issue":"1","key":"1568_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3233\/JAD-210075","volume":"81","author":"S Ikeda","year":"2021","unstructured":"Ikeda S, Mimura M, Ikeda M, Wada-Isoe K, Azuma M, Inoue S, Tomita K. Economic Burden of Alzheimer\u2019s Disease Dementia in Japan. J Alzheimers Dis. 2021;81(1):309\u201319.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1568_CR4","first-page":"362","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023;10(3):362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"key":"1568_CR5","unstructured":"Eisai. \u201cLEQEMBI\u00ae Intravenous Infusion\u201d (Lecanemab) Approved for the Treatment of Alzheimer\u2019s Disease in Japan. (https:\/\/www.eisai.com\/news\/2023\/news202359.html): Accessed on 25 Sept 2023."},{"key":"1568_CR6","unstructured":"Biogen. \u201cLEQEMBI\u00ae\u201d (Lecanemab) Approved for the Treatment of Alzheimer\u2019s Disease in China. (https:\/\/investors.biogen.com\/news-releases\/news-release-details\/leqembir-lecanemab-approved-treatment-alzheimers-disease-china) : Accessed on 9 Jan 2024."},{"key":"1568_CR7","unstructured":"Eisai. \u201cLEQEMBI\u00ae Intravenous Infusion\u201d (Lecanemab) for the Treatment of Alzheimer\u2019s Disease to be Launched in Japan on December 20. (https:\/\/www.eisai.com\/news\/2023\/news202374.html): Accessed on 13 Dec 2023."},{"key":"1568_CR8","unstructured":"Ministry of Health, Labour, and Welfare. reference materials for Central Social Insurance Medical Council, 572nd General Meeting (on December 13, 2023). [Article in Japanese] (https:\/\/www.mhlw.go.jp\/content\/001179210.pdf): Accessed on 25 July 2024."},{"key":"1568_CR9","unstructured":"Mattke, S., Hl\u00e1vka, J. P., Yoong, J., Wang, M., Goto, R. (2019). Assessing the preparedness of the Japanese health care system infrastructure for an Alzheimer\u2019s treatment."},{"issue":"12","key":"1568_CR10","doi-asserted-by":"publisher","first-page":"5596","DOI":"10.1002\/alz.13348","volume":"19","author":"S Mattke","year":"2023","unstructured":"Mattke S, Loh WK, Yuen KH, Yoong J. Preparedness of China\u2019s health care system to provide access to a disease-modifying Alzheimer\u2019s treatment. Alzheimers Dement. 2023;19(12):5596\u2013604.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1568_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5694\/mja2.51880","volume":"218","author":"A Brodtmann","year":"2023","unstructured":"Brodtmann A, Darby D, Oboudiyat C, et al. Assessing preparedness for Alzheimer disease-modifying therapies in Australasian health care systems. Med J Aust. 2023;218(6):247\u20139.","journal-title":"Med J Aust"},{"key":"1568_CR12","unstructured":"Ministry of Health, Labour, and Welfare. LEQEMBI package insert [Article in Japanese]. (https:\/\/www.info.pmda.go.jp\/go\/pack\/1190408A1025_1_01\/): Accessed on 13 Dec 2023."},{"key":"1568_CR13","unstructured":"Ministry of Health, Labour, and Welfare. LEQEMBI Optimal Use Guideline [Article in Japanese]. (https:\/\/www.mhlw.go.jp\/content\/12404000\/001178607.pdf): Accessed on 13 Dec 2023."},{"issue":"2","key":"1568_CR14","first-page":"211","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, et al. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer\u2019s Disease Treated with Anti-Amyloid Beta Therapy. J Prev Alzheimers Dis. 2022;9(2):211\u201320.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"1568_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13643-020-01482-8","volume":"9","author":"J D\u00e9ry","year":"2020","unstructured":"D\u00e9ry J, Ruiz A, Routhier F, et al. A systematic review of patient prioritization tools in non-emergency healthcare services. Syst Rev. 2020;9(1):227.","journal-title":"Syst Rev"},{"key":"1568_CR16","unstructured":"Hadorn DC. Setting priorities for waiting lists: defining our terms. Steering Committee of the Western Canada Waiting List Project. CMAJ. 2000;163(7):857\u201360."},{"key":"1568_CR17","doi-asserted-by":"crossref","unstructured":"Noseworthy TW, McGurran JJ, Hadorn DC; Steering Committee of the Western Canada Waiting List Project. Waiting for scheduled services in Canada: development of priority-setting scoring systems. J Eval Clin Pract. 2003;9(1):23\u201331.","DOI":"10.1046\/j.1365-2753.2003.00377.x"},{"issue":"1","key":"1568_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12135","volume":"7","author":"K Sato","year":"2021","unstructured":"Sato K, Ihara R, Suzuki K, et al. Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study. Alzheimers Dement (N Y). 2021;7(1): e12135.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"7","key":"1568_CR19","doi-asserted-by":"publisher","DOI":"10.2196\/26284","volume":"23","author":"K Sato","year":"2021","unstructured":"Sato K, Niimi Y, Ihara R, et al. Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational Study. J Med Internet Res. 2021;23(7): e26284.","journal-title":"J Med Internet Res"},{"issue":"4","key":"1568_CR20","first-page":"208","volume":"7","author":"PS Aisen","year":"2020","unstructured":"Aisen PS, Sperling RA, Cummings J, et al. The Trial-Ready Cohort for Preclinical\/Prodromal Alzheimer\u2019s Disease (TRC-PAD) Project: An Overview. J Prev Alzheimers Dis. 2020;7(4):208\u201312.","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"1568_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3233\/JAD-161294","volume":"60","author":"C Li","year":"2017","unstructured":"Li C, Neugroschl J, Luo X, et al. The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults. J Alzheimers Dis. 2017;60(2):427\u201337.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1568_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/2050-7283-1-30","volume":"1","author":"P Maruff","year":"2013","unstructured":"Maruff P, Lim YY, Darby D, et al. Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer\u2019s disease. BMC Psychol. 2013;1(1):30.","journal-title":"BMC Psychol"},{"issue":"3","key":"1568_CR23","first-page":"661","volume":"11","author":"K Sato","year":"2024","unstructured":"Sato K, Niimi Y, Ihara R, Suzuki K, Iwata A, Iwatsubo T. Usability of a Web-Based Registry for Preclinical Alzheimer\u2019s Disease: Implications from a Cross-Sectional Online Survey. J Prev Alzheimers Dis. 2024;11(3):661\u201371.","journal-title":"J Prev Alzheimers Dis"},{"key":"1568_CR24","unstructured":"Nakashima S, Sato K, Niimi Y, Toda T, Iwatsubo T. Analyzing Response Rates and Respondent Demographics in Online Surveys Assessing Public Perception of Alzheimer\u2019s Disease-Modifying Therapies. Alzheimer's Association International Conference, 2024. 84862."},{"key":"1568_CR25","doi-asserted-by":"publisher","first-page":"1320329","DOI":"10.3389\/frdem.2023.1320329","volume":"2","author":"K Sato","year":"2024","unstructured":"Sato K, Niimi Y, Ihara R, Suzuki K, Iwata A, Iwatsubo T. APOE-\u03b54 allele [s]-associated adverse events reported from placebo arm in clinical trials for Alzheimer\u2019s disease: implications for anti-amyloid beta therapy. Frontiers in Dementia. 2024;2:1320329.","journal-title":"Frontiers in Dementia"},{"issue":"1","key":"1568_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, Maechler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. J Stat Softw. 2015;67(1):1\u201348. https:\/\/doi.org\/10.18637\/jss.v067.i01.","journal-title":"J Stat Softw"},{"issue":"9","key":"1568_CR27","first-page":"1078","volume":"29","author":"AC Wright","year":"2023","unstructured":"Wright AC, Lin GA, Whittington MD, et al. The effectiveness and value of lecanemab for early Alzheimer disease: A summary from the Institute for Clinical and Economic Review\u2019s California Technology Assessment Forum. J Manag Care Spec Pharm. 2023;29(9):1078\u201383.","journal-title":"J Manag Care Spec Pharm"},{"key":"1568_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100657","volume":"29","author":"L J\u00f6nsson","year":"2023","unstructured":"J\u00f6nsson L, Wimo A, Handels R, et al. The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer\u2019s disease: an EADC-EC viewpoint. Lancet Reg Health Eur. 2023;29: 100657.","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"1568_CR29","first-page":"1044","volume":"20","author":"L Crax\u00ec","year":"2016","unstructured":"Crax\u00ec L, Sacchini D, Refolo P, et al. Prioritization of high-cost new drugs for HCV: making sustainability ethical. Eur Rev Med Pharmacol Sci. 2016;20(6):1044\u201351.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1568_CR30","unstructured":"Appropriate Use Guideline Development Committee. Appropriate use guideline of cerebrospinal fluid and blood-based biomarkers and APOE tests for dementia (2nd edition) [Article in Japanese]. 2023. (https:\/\/www.jpn-geriat-soc.or.jp\/info\/important_info\/pdf\/20231003_01_01.pdf): Accessed on 13 Dec 2023."},{"key":"1568_CR31","unstructured":"Japan Health Policy NOW. Payment System. (https:\/\/japanhpn.org\/en\/finan2\/): Accessed on 30 Jan 2024."},{"issue":"2","key":"1568_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s12687-024-00697-9","volume":"15","author":"K Sato","year":"2024","unstructured":"Sato K, Niimi Y, Ihara R, Iwata A, Ikeuchi T, Iwatsubo T. Advertisement by medical facilities as an opportunity route of APOE genetic testing in Japan: a website analysis. J Community Genet. 2024;15(2):195\u2013204.","journal-title":"J Community Genet"}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01568-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01568-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01568-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T20:02:19Z","timestamp":1727899339000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01568-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1568"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01568-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4553664\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"9 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The J-TRC webstudy was approved by the University of Tokyo Graduate School of Medicine Institutional Ethics Committee (ID:2019132NI-(3)), and online informed consent was obtained from individual participants upon registration. The online survey was also approved by the local ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"205"}}